Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ZII
|
|||
| Former ID |
DAP000933
|
|||
| Drug Name |
Eszopiclone
|
|||
| Synonyms |
Esopiclone; Estorra; Lunesta; Lunivia; Estorra (TN); Eszopiclone [USAN:INN]; KS-1055; SEP-0227018; SEP-0227108; SEP-190; SEP-225441; Eszopiclone (JAN/USAN/INN); [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; (plus)-Zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Insomnia [ICD-11: 7A00-7A0Z] | Approved | [1], [2] | |
| Therapeutic Class |
Hypnotics and Sedatives
|
|||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H17ClN6O3
|
|||
| Canonical SMILES |
CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
|
|||
| InChI |
1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
|
|||
| InChIKey |
GBBSUAFBMRNDJC-INIZCTEOSA-N
|
|||
| CAS Number |
CAS 138729-47-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8719708, 12015386, 14927588, 17396794, 25819909, 26612818, 29215492, 44256005, 46505809, 49666409, 50070163, 50070571, 50071326, 57408900, 61128015, 75503740, 87246620, 89736090, 92714227, 103558705, 104170161, 110105491, 117478867, 121362188, 121362390, 125169642, 126592991, 126627684, 126629616, 126655556, 131298420, 131378756, 134221729, 135114014, 135696725, 137002949, 141949765, 144205286, 152035015, 160963748, 162957823, 164196530, 164832496, 170465445, 172080786, 175265884, 175271194, 175610981, 178104001, 179149892
|
|||
| ChEBI ID |
CHEBI:53760
|
|||
| ADReCS Drug ID | BADD_D00837 | |||
| SuperDrug ATC ID |
N05CF04
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Bacteroides coprophilus DSM 18228 (log2FC = -0.44; p = 0.011). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens ATCC25986
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Collinsella aerofaciens ATCC25986 (log2FC = -0.339; p = 0.004). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta ATCC 25559
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Eggerthella lenta ATCC 25559 (log2FC = -0.458; p = 0.011). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Bryantia formatexigens DSM 14469
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Bryantia formatexigens DSM 14469 (log2FC = -0.429; p = 0.009). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Clostridium sp. (log2FC = -1.19; p = 0.002). | |||
|
Studied Microbe: Clostridium symbiosum ATCC 14940
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Clostridium symbiosum ATCC 14940 (log2FC = -0.324; p = 0.034). | |||
|
Studied Microbe: Eubacterium hallii DSM3353
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Eubacterium hallii DSM3353 (log2FC = -0.736; p = 0.008). | |||
|
Studied Microbe: Eubacterium rectale ATCC 33656
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Eubacterium rectale ATCC 33656 (log2FC = -0.599; p = 0.004). | |||
|
Studied Microbe: Ruminococcus lactaris ATCC 29176
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Ruminococcus lactaris ATCC 29176 (log2FC = -0.348; p = 0.039). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Tissierellales | ||||
|
Studied Microbe: Anaerococcus hydrogenalis DSM 7454
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Eszopiclone can be metabolized by Anaerococcus hydrogenalis DSM 7454 (log2FC = -0.372; p = 0.028). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Translocator protein (TSPO) | Target Info | Agonist | [4], [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| HTLV-I infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7429). | |||
| REF 2 | Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9. | |||
| REF 5 | Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.